Minireviews
Copyright ©The Author(s) 2017.
World J Gastroenterol. Aug 28, 2017; 23(32): 5875-5886
Published online Aug 28, 2017. doi: 10.3748/wjg.v23.i32.5875
Table 3 Principal clinical trials with nab-paclitaxel in pancreatic cancer “early settings”
Study IDSettingStudy drugsPhaseStatus
NCT01964430AdjuvantNab-paclitaxel + Gemcitabine vs GemcitabineIIIRecruiting
NCT02506842AdjuvantNab-paclitaxel + Gemcitabine vs OFFIIIRecruiting
NCT02023021AdjuvantNab-paclitaxel + GemcitabineIIRecruiting
NCT02125136NeoadjuvantNab-paclitaxel + Gemcitabine vs FOLFIFINOXIIRecruiting
NCT02243007NeoadjuvantNab-paclitaxel + Gemcitabine vs FOLFIFINOXIIRecruiting
NCT02717091Neoadjuvant/borderline resectableNab-paclitaxel + Gemcitabine vs FOLFIFINOXIIRecruiting
NCT02481635NEO/adjuvantNab-paclitaxel + Gemcitabine + radiotherapyI-IIRecruiting
NCT01431794NeoadjuvantNab-paclitaxel + Gemcitabine + LDE-225I-IIActive not recruiting
NCT02588443NEO/adjuvantNab-paclitaxel + Gemcitabine + RO7009789IRecruiting
NCT02272738NeoadjuvantNab-paclitaxel + Gemcitabine + radiotherapyIRecruiting
NCT02506803NeoadjuvantNab-paclitaxel + GemcitabineIRecruiting
NCT02427841ResectableNab-paclitaxel + Gemcitabine followed by radiotherapyIIRecruiting
NCT02550327ResectableNab-paclitaxel + Gemcitabine + Cisplatin + AnakinraIRecruiting
NCT02210559Locally advancedNab-paclitaxel + Gemcitabine + FG-3019I-IIRecruiting
NCT02394535Locally advancedNab-paclitaxel + Capecitabine + radiotherapyIRecruiting
NCT02124369Borderline unresectableNab-paclitaxel + GemcitabineIIRecruiting
NCT02043730Unresectable locally advacedNab-paclitaxel + GemcitabineIIRecruiting
NCT02207465Unresectable locally advancedNab-paclitaxel + Gemcitabine + radiotherapyIRecruiting
NCT02272738Unresectable locally advancedNab-paclitaxel + GemcitabineIRecruiting
NCT01978184PreoperativeNab-paclitaxel + Gemcitabine + HydroxychloroquineIIRecruiting
NCT02427841PreoperativeNab-paclitaxel + Gemcitabine + radiotherapyIIRecruiting
NCT02723331PreoperativeNab-paclitaxel + Gemcitabine followed by SBRTIIRecruiting
NCT02930902PreoperativeNab-paclitaxel + Gemcitabine + Pembrolizumab + ParicalcitolIRecruiting